Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy

MLA

Paul M. Ridker, et al. “Ability of VKORC1 and CYP2C9 to Predict Therapeutic Warfarin Dose during the Initial Weeks of Therapy.” Journal of Thrombosis and Haemostasis : JTH, vol. 8, no. 1, Oct. 2009. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cfa041c868714d1db60c3bb55ebf511b&authtype=sso&custid=ns315887.

APA

Paul M. Ridker, Nicholas Ferder, Jenine K. Harris, Cristi R. King, Charles S. Eby, Tusar Giri, Paul E. Milligan, Elena Deych, Robert J. Glynn, Howard L. McLeod, Samuel Z. Goldhaber, & Brian F. Gage. (2009). Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. Journal of Thrombosis and Haemostasis : JTH, 8(1).

Chicago

Paul M. Ridker, Nicholas Ferder, Jenine K. Harris, Cristi R. King, Charles S. Eby, Tusar Giri, Paul E. Milligan, et al. 2009. “Ability of VKORC1 and CYP2C9 to Predict Therapeutic Warfarin Dose during the Initial Weeks of Therapy.” Journal of Thrombosis and Haemostasis : JTH 8 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....cfa041c868714d1db60c3bb55ebf511b&authtype=sso&custid=ns315887.